selurampanel
Small moleculeexperimental
Selurampanel is a drug closely related to the quinoxalinedione series which acts as a competitive antagonist of the AMPA and kainate receptors and, as of 2015, is being investigated in clinical trials by Novartis for the treatment of epilepsy. It has also been studied in the acute treatment of migraine, and was found to produce some pain relief, but with a relatively high rate of side effects. — Wikipedia
Clinical trial activity
10 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
10
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2008 (NCT00784212)
Timeline
2000s
- Jan 1, 2008
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Glutamate receptor ionotropic kainateANTAGONIST
Glutamate receptor ionotropic kainate antagonist
- Glutamate receptor ionotropic AMPAANTAGONIST
Glutamate receptor ionotropic AMPA antagonist
Competitive antagonist of the AMPA receptor.
Chemistry & pharmacology
Loading structure…
SMILES
CC(C)c1cc2[nH]c(=O)n(NS(C)(=O)=O)c(=O)c2cc1-c1ccnn1C- Mol. weight
- 377.43 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaSelurampanel ↗
- ChEMBLCHEMBL3545042 ↗
Also known as
- bgg492
- bgg492
- bgg492
- bgg-492
- bgg-492
- selurampanel
- selurampanel
- selurampanel
- selurampanel
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01649050 | Phase 2 | Oct 1, 2016 | Novartis |
| NCT01617941 | Phase 2 | May 1, 2016 | Novartis |
| NCT02150213 | Phase 2 | Aug 1, 2014 | Novartis |
| NCT01338805 | Phase 2 | Jun 1, 2011 | Novartis |
| NCT01302873 | Phase 2 | Jan 1, 2011 | Novartis |
| NCT01167335 | Phase 2 | Aug 1, 2010 | Novartis |
| NCT01147003 | Phase 2 | Jun 1, 2010 | Novartis |
| NCT00892203 | Phase 2 | Apr 1, 2009 | Novartis |
| NCT00887861 | Phase 2 | Mar 1, 2009 | Novartis |
| NCT00784212 | Phase 2 | Oct 1, 2008 | Novartis |
Showing 10 of 10 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Novartis | For profit | 10 | 10 | 1 | 2008 |
1 organizations
Page 1 / 1